Shamburg News · 8-K filed Nov 12, 2026, 4:21 PM EST

Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update

CRDF · Cardiff Oncology, Inc.

  • Earnings
  • Other event
  • Materiality: high

On November 12, 2026, Cardiff Oncology reported financial results for the third quarter ended September 30, 2026, and provided a business update on its Phase 2 onvansertib trial in first-line RAS-mutated mCRC. For the quarter, the company reported royalty revenues of $171 thousand and a net loss of $8,857 thousand, compared with $11,258 thousand a year earlier, and net loss per share of $(0.12). As of September 30, 2026, Cardiff had approximately $33.8 million in cash, cash equivalents, and short-term investments, which it believes will fund operations to the end of the third quarter of 2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-458500.

Written from the filing by Shamburg Markets. Figures are as reported by the company.